Adenosquamous Cell Lung Cancer Stage I

Adenosquamous carcinoma of the lung stage I is a rare and aggressive form of lung cancer that contains both glandular and squamous cell components. Though it represents only a small percentage of all lung cancers, early detection at stage I offers the best chance for successful treatment and long-term survival.

Table of contents

• What is Adenosquamous Carcinoma of the Lung?
• Understanding Stage I Disease
• Symptoms and Signs
• Causes and Risk Factors
• Diagnosis
• Treatment Options
• Outlook and Survival

What is Adenosquamous Carcinoma of the Lung?

Adenosquamous carcinoma of the lung is a relatively rare subtype of non-small-cell lung cancer (NSCLC), defined as a malignancy containing components of both lung adenocarcinoma (glandular cancer cells) and lung squamous cell carcinoma (cancer cells from the flat, scale-like cells lining the airways). According to current medical classification, each of these two components must comprise at least 10% of the tumor to meet the diagnostic criteria.^[1][5]

This dual nature makes adenosquamous carcinoma a unique entity among lung cancers. Although it has biological characteristics of both adenocarcinoma and squamous cell carcinoma, it is not simply a hybrid of these two components. The cancer accounts for approximately 2% to 4% of all lung cancers, making it considerably less common than typical adenocarcinoma or squamous cell carcinoma.^[5]

• Lungs
• Bronchi (airways)
• Bronchioles (small airways)
• Alveoli (air sacs)

Due to its aggressive nature, adenosquamous carcinoma is associated with a poorer prognosis than pure adenocarcinomas or squamous cell carcinomas of the lung. Studies indicate that these tumors at diagnosis have higher rates of lymph node invasion and tend to metastasize more rapidly than other non-small-cell lung cancer subtypes.^[3][5]

Understanding Stage I Disease

Stage I lung cancer is the second-earliest stage of the disease and is also called early-stage lung cancer. At this stage, abnormal cells in the airways have turned into cancer, but the tumor is only in the lungs and has not spread to the lymph nodes.^[4]

For adenosquamous carcinoma, stage I is divided into two main subtypes based on tumor size and characteristics. Stage IA tumors are no larger than 3 centimeters (about the size of a walnut) and are confined within the lung tissue. This stage is further subdivided into IA1, IA2, and IA3 based on specific size measurements. Stage IB includes tumors larger than 3 centimeters but not more than 4 centimeters, or smaller tumors that have certain additional features such as involvement of the main airway or spread to the membrane covering the lung surface.^[4]

A study analyzing 1,251 patients with stage I adenosquamous lung cancer found that the mean tumor size was 26.2 mm (approximately 1 inch), with 656 patients having stage IA disease and 595 having stage IB disease. The mean age at diagnosis was 70 years, with male and white patients accounting for larger proportions.^[6]

Symptoms and Signs

Many people with early-stage lung cancer, including stage I adenosquamous carcinoma, may not experience any symptoms initially. When symptoms do occur, they are similar to other forms of lung cancer and may include:^[3]

• Persistent cough that lasts 3 weeks or more, or a cough that gets worse
• Shortness of breath
• Chest pain, or pain in the ribs or shoulders
• Hemoptysis (coughing up blood or blood-stained mucus)
• Fatigue or weakness
• Unexplained weight loss
• Loss of appetite
• Hoarseness
• Frequent infections such as bronchitis or pneumonia that don’t improve or keep coming back

Because early-stage disease often produces minimal or no symptoms, many cases of adenosquamous carcinoma are discovered through imaging studies performed for other reasons or during routine screening in high-risk individuals.

Causes and Risk Factors

While the exact cause of adenosquamous carcinoma remains uncertain, several risk factors associated with lung cancer in general are also applicable to this rare subtype. As with other lung cancers, the average age at diagnosis is about 70 years, it affects more men than women, and most patients are current or former smokers.^[1]

The major risk factors include:^[3]

• Smoking: The primary risk factor for most lung cancers, including cigarettes, pipes, and cigars
• Exposure to carcinogens: Including asbestos, radon, and certain industrial substances such as arsenic, chromium, beryllium, and nickel
• Previous radiation therapy: Especially to the chest area or breast
• Family history of lung cancer
• Exposure to secondhand smoke

Adenosquamous carcinoma is associated with cigarette smoke, although the relationship between smoking and this specific subtype continues to be studied. The underlying biology driving adenosquamous carcinoma differs from more typical non-small-cell lung cancer subtypes, suggesting unique molecular and genomic features that remain poorly understood.^[5]

Diagnosis

Diagnosing adenosquamous carcinoma of the lung can be extremely challenging. The mixed nature of the tumor, with its intratumoral heterogeneity (different cell types within the same tumor), often hinders and may delay accurate diagnosis. Studies suggest that adenosquamous carcinoma is misdiagnosed as adenocarcinoma or squamous cell carcinoma in at least half of biopsies prior to surgical pathology confirming the diagnosis. In one retrospective study, nearly all cases (98%) were either misdiagnosed or undiagnosed before surgery.^[5]

Different types of biopsy samples may yield different results. For example, one patient eventually diagnosed with adenosquamous carcinoma had three different preliminary results: squamous cell carcinoma on bronchial lavage and biopsy, adenocarcinoma on special tissue staining tests, and undifferentiated non-small-cell lung cancer on fluid analysis.^[5]

To diagnose adenosquamous carcinoma, doctors typically employ a combination of methods:^[3]

• Imaging studies: Chest X-ray or CT scan to identify abnormal masses or nodules in the lungs
• Bronchoscopy: A procedure where a thin tube with a camera is inserted through the mouth or nose into the airways to view the lungs and obtain tissue samples
• Biopsy: Either via needle aspiration or surgical methods, to examine tissue under a microscope and confirm the diagnosis

While a diagnosis can be made using small biopsy and fluid samples, a definitive diagnosis often requires larger samples, such as several core biopsies or complete surgical removal of the tumor, to fully evaluate all components of the tumor. Comprehensively evaluating entire tumor specimens helps doctors properly classify the disease and determine the best treatment approach.^[5]

Once adenosquamous carcinoma is confirmed, staging procedures determine the extent of the disease. For stage I tumors, imaging confirms that the cancer is confined to the lung without spread to lymph nodes or distant organs.

Treatment Options

Treatment strategies for stage I adenosquamous carcinoma of the lung depend on the specific characteristics of the tumor, the patient’s overall health, and other individual factors. Early-stage disease offers the best opportunity for curative treatment.

Surgery

Surgery is the primary treatment for stage I adenosquamous carcinoma. The goal is complete removal of the tumor and surrounding lung tissue. Types of surgical procedures include:^[3]

• Lobectomy: Removal of the lobe of the lung containing the tumor (the most common procedure)
• Segmentectomy: Removal of a smaller portion of the lung
• Pneumonectomy: Removal of an entire lung (less common for stage I disease)

A large study of stage I adenosquamous carcinoma found that patients who received surgery had significantly better outcomes than those who received only chemotherapy. The research demonstrated that surgical removal of the tumor provides the best chance for long-term survival in early-stage disease.^[6]

Chemotherapy

The role of adjuvant chemotherapy (chemotherapy given after surgery) for stage I adenosquamous carcinoma continues to be studied. Platinum-based chemotherapy, which uses drugs containing platinum compounds combined with other cancer-fighting medications, is the standard approach when chemotherapy is recommended.^[1]

Because adenosquamous carcinoma contains both adenocarcinoma and squamous cell components, chemotherapy regimens are designed to target both cell types. A common combination includes taxol and carboplatin. The decision to add chemotherapy after surgery depends on various factors, including the exact size and characteristics of the tumor, whether it has reached the edge of the removed tissue, and the patient’s overall health.^[6]

Other Treatment Approaches

Additional treatment options that may be considered include:^[3]

• Radiation therapy: Using high-energy rays to target cancer cells, sometimes used if surgery is not possible
• Targeted therapy: Drugs designed to target specific genetic mutations or characteristics of the cancer cells
• Immunotherapy: Treatment that helps the body’s own immune system fight the cancer

For patients with adenosquamous carcinoma that has specific genetic changes, targeted therapies may be effective. Studies show that approximately 30% of adenosquamous carcinomas have EGFR mutations (changes in the epidermal growth factor receptor gene), and drugs called EGFR tyrosine kinase inhibitors, such as erlotinib and gefitinib, can be effective therapeutic strategies for advanced disease with these mutations. About 5% of adenosquamous carcinomas have ALK rearrangements, which may respond to drugs like crizotinib.^[1]

Immune checkpoint blockade therapy may be a potential treatment choice for adenosquamous carcinoma patients. Studies have found that PD-L1 expression (a protein marker that can predict response to immunotherapy) is present in a portion of these tumors, with one study showing 11% expression in the adenocarcinoma component and 28% in the squamous component.^[1]

Outlook and Survival

Stage I adenosquamous carcinoma of the lung is often curable when treated appropriately, and most people can expect to live 5 years or longer. However, the prognosis for adenosquamous carcinoma is generally more guarded than for pure adenocarcinoma or squamous cell carcinoma at the same stage.^[3]

Research comparing survival rates shows important differences. In a large population-based study, 5-year survival rates after surgery for early-stage cancers were 65% for adenosquamous carcinoma compared to 69% for squamous cell carcinoma and 77% for adenocarcinoma. While these differences may seem modest, they are statistically significant and reflect the more aggressive nature of adenosquamous carcinoma.^[5]

Several factors influence individual prognosis for stage I disease, including the exact tumor size, whether cancer cells are found at the edges of the removed tissue, the patient’s overall health and lung function, and the presence of specific genetic mutations that may respond to targeted therapies. Adenosquamous carcinomas can also be further classified based on the proportions of adenocarcinoma and squamous cell components, with structure-balanced tumors (those with roughly equal amounts of each component) reported to have better outcomes than tumors dominated by one component.^[5]

Regular follow-up care after treatment is essential, as it allows doctors to monitor for any signs of cancer recurrence and manage any long-term effects of treatment. This typically includes periodic imaging studies and physical examinations according to a schedule determined by the treatment team.